Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
10.6
USD
|
+9.50%
|
|
+12.53%
|
+16.10%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
763.8
|
935.7
|
595.5
|
461.6
|
522.7
|
620.4
|
-
|
-
|
Enterprise Value (EV)
1 |
542.8
|
697.2
|
501.9
|
402.2
|
279.9
|
444.5
|
547.1
|
749.6
|
P/E ratio
|
-2.73
x
|
-8.56
x
|
-5.06
x
|
-2.22
x
|
-2.32
x
|
-2.05
x
|
-2.79
x
|
-6.21
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
766
x
|
14.8
x
|
3.79
x
|
1.74
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
410
x
|
10.6
x
|
3.34
x
|
2.1
x
|
EV / EBITDA
|
-5.11
x
|
-5.56
x
|
-3.73
x
|
-2.34
x
|
-1.68
x
|
-1.87
x
|
-2.66
x
|
-10.4
x
|
EV / FCF
|
-14.8
x
|
-9.86
x
|
-3.09
x
|
-2.73
x
|
-2.01
x
|
-1.68
x
|
-2.74
x
|
-5.05
x
|
FCF Yield
|
-6.75%
|
-10.1%
|
-32.3%
|
-36.7%
|
-49.7%
|
-59.6%
|
-36.5%
|
-19.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
24,527
|
28,166
|
30,276
|
41,144
|
57,253
|
58,524
|
-
|
-
|
Reference price
2 |
31.14
|
33.22
|
19.67
|
11.22
|
9.130
|
10.60
|
10.60
|
10.60
|
Announcement Date
|
3/19/20
|
3/30/21
|
3/1/22
|
2/28/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.682
|
41.82
|
163.7
|
356.3
|
EBITDA
1 |
-106.2
|
-125.3
|
-134.6
|
-171.8
|
-166.7
|
-237.2
|
-205.8
|
-72.29
|
EBIT
1 |
-106.2
|
-125.7
|
-135.1
|
-172.4
|
-167.3
|
-261.3
|
-209.5
|
-76.11
|
Operating Margin
|
-
|
-
|
-
|
-
|
-24,532.55%
|
-624.82%
|
-127.98%
|
-21.36%
|
Earnings before Tax (EBT)
1 |
-255.1
|
-129.1
|
-143.9
|
-197.7
|
-201.6
|
-310.8
|
-266.1
|
-139.8
|
Net income
1 |
-255.1
|
-129.1
|
-143.9
|
-197.7
|
-201.6
|
-310.8
|
-266.1
|
-139.8
|
Net margin
|
-
|
-
|
-
|
-
|
-29,558.94%
|
-743.35%
|
-162.61%
|
-39.23%
|
EPS
2 |
-11.41
|
-3.880
|
-3.890
|
-5.050
|
-3.930
|
-5.158
|
-3.798
|
-1.708
|
Free Cash Flow
1 |
-36.64
|
-70.73
|
-162.4
|
-147.6
|
-139.2
|
-265
|
-199.6
|
-148.6
|
FCF margin
|
-
|
-
|
-
|
-
|
-20,412.61%
|
-633.74%
|
-121.97%
|
-41.69%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/20
|
3/30/21
|
3/1/22
|
2/28/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.682
|
1.912
|
5.661
|
11.31
|
22.9
|
29.01
|
42.2
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-56.38
|
-53.96
|
-47.65
|
-
|
-
|
EBIT
1 |
-33.04
|
-37.91
|
-45.36
|
-42.53
|
-46.64
|
-30.08
|
-31.7
|
-35.66
|
-69.87
|
-69.95
|
-68.32
|
-66.25
|
-59.54
|
-59.67
|
-49.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-10,245.45%
|
-3,658.68%
|
-1,206.79%
|
-585.73%
|
-259.93%
|
-205.65%
|
-116.35%
|
Earnings before Tax (EBT)
1 |
-35.83
|
-40.66
|
-50.92
|
-51.09
|
-55.05
|
-37.81
|
-40.96
|
-43.24
|
-79.57
|
-82.85
|
-77.55
|
-75.22
|
-67.77
|
-67.8
|
-61.9
|
Net income
1 |
-35.83
|
-40.66
|
-50.92
|
-51.09
|
-55.05
|
-37.81
|
-40.96
|
-43.24
|
-79.57
|
-82.85
|
-77.55
|
-75.22
|
-67.77
|
-67.8
|
-61.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,667.01%
|
-4,333.26%
|
-1,369.76%
|
-665.05%
|
-295.86%
|
-233.68%
|
-146.68%
|
EPS
2 |
-0.9500
|
-1.070
|
-1.330
|
-1.320
|
-1.330
|
-0.8900
|
-0.8400
|
-0.7600
|
-1.390
|
-1.420
|
-1.380
|
-1.343
|
-1.103
|
-1.075
|
-1.060
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/10/22
|
8/2/22
|
11/8/22
|
2/28/23
|
5/10/23
|
8/10/23
|
11/9/23
|
3/7/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
129
|
Net Cash position
1 |
221
|
238
|
93.6
|
59.4
|
243
|
176
|
73.3
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1.788
x
|
Free Cash Flow
1 |
-36.6
|
-70.7
|
-162
|
-148
|
-139
|
-265
|
-200
|
-149
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
-3.810
|
-1.100
|
-0.6400
|
Capex
1 |
0.13
|
1.04
|
0.33
|
1.04
|
1.63
|
1.06
|
2.49
|
2.4
|
Capex / Sales
|
-
|
-
|
-
|
-
|
239.59%
|
2.54%
|
1.52%
|
0.67%
|
Announcement Date
|
3/19/20
|
3/30/21
|
3/1/22
|
2/28/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
10.6
USD Average target price
22.29
USD Spread / Average Target +110.24% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.10% | 620M | | +51.85% | 57.87B | | +41.42% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|